Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia
Eduard Parellada, Miquel Bioque
CNS Drugs (2016) Vol. 30, Iss. 8, pp. 689-701
Closed Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Thomas R. E. Barnes, Richard Drake, Carol Paton, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 1, pp. 3-78
Open Access | Times Cited: 513
Solid implantable devices for sustained drug delivery
Elizabeth Magill, Sara Demartis, Elisabetta Gavini, et al.
Advanced Drug Delivery Reviews (2023) Vol. 199, pp. 114950-114950
Open Access | Times Cited: 71
Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis
Dee Lin, Philippe Thompson‐Leduc, Isabelle Ghelerter, et al.
CNS Drugs (2021) Vol. 35, Iss. 5, pp. 469-481
Open Access | Times Cited: 85
Disruptions in Care for Medicare Beneficiaries With Severe Mental Illness During the COVID-19 Pandemic
Alisa B. Busch, Haiden A. Huskamp, Pushpa Raja, et al.
JAMA Network Open (2022) Vol. 5, Iss. 1, pp. e2145677-e2145677
Open Access | Times Cited: 47
3D-printed implantable devices with biodegradable rate-controlling membrane for sustained delivery of hydrophobic drugs
Camila J. Picco, Juan Domínguez‐Robles, Emilia Utomo, et al.
Drug Delivery (2022) Vol. 29, Iss. 1, pp. 1038-1048
Open Access | Times Cited: 39
<p>Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire</p>
Clifton Blackwood, Panna Sanga, Isaac Nuamah, et al.
Patient Preference and Adherence (2020) Vol. Volume 14, pp. 1093-1102
Open Access | Times Cited: 51
Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia
Cheng-Yi Huang, Su‐Chen Fang, Yu‐Hsuan Joni Shao
JAMA Network Open (2021) Vol. 4, Iss. 5, pp. e218810-e218810
Open Access | Times Cited: 48
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Seiya Miyamoto, W. Wolfgang Fleischhacker
Current Treatment Options in Psychiatry (2017) Vol. 4, Iss. 2, pp. 117-126
Open Access | Times Cited: 60
Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
Michael W. Jann, Scott Penzak
CNS Drugs (2018) Vol. 32, Iss. 3, pp. 241-257
Closed Access | Times Cited: 55
Persistent Barriers to the Use of Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia
Jean‐Pierre Lindenmayer, Ira D. Glick, Hiteshkumar Talreja, et al.
Journal of Clinical Psychopharmacology (2020) Vol. 40, Iss. 4, pp. 346-349
Closed Access | Times Cited: 42
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial
John M. Kane, Roy Eshet, Eran Harary, et al.
CNS Drugs (2024) Vol. 38, Iss. 8, pp. 625-636
Open Access | Times Cited: 6
Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study
Miquel Bioque, Eduard Parellada, Clemente García‐Rizo, et al.
European Psychiatry (2020) Vol. 63, Iss. 1
Open Access | Times Cited: 33
Current and emerging long-acting antipsychotics for the treatment of schizophrenia
Renato de Filippis, Pasquale De Fazio, Raffaele Gaetano, et al.
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 7, pp. 771-790
Closed Access | Times Cited: 32
Barriers and Supports in eHealth Implementation among People with Chronic Cardiovascular Ailments: Integrative Review
Sophia Herrera, Alide Salazar Molina, Gabriela Nazar
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 14, pp. 8296-8296
Open Access | Times Cited: 20
Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics &ndash; expert consensus survey part 1
Martha Sajatovic, Ruth Ross, Susan N. Legacy, et al.
Neuropsychiatric Disease and Treatment (2018) Vol. Volume 14, pp. 1463-1474
Open Access | Times Cited: 35
<p>Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia</p>
Maju Mathews, Srihari Gopal, Isaac Nuamah, et al.
Neuropsychiatric Disease and Treatment (2019) Vol. Volume 15, pp. 1365-1379
Open Access | Times Cited: 32
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study
Sally Mustafa, Joanna Bougie, Maı̈a Miguelez, et al.
BMC Psychiatry (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 32
Long‐acting antipsychotic medication as first‐line treatment of first‐episode psychosis with comorbid substance use disorder
Amal Abdel‐Baki, Dominic Thibault, Sofia Medrano, et al.
Early Intervention in Psychiatry (2019) Vol. 14, Iss. 1, pp. 69-79
Closed Access | Times Cited: 31
What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review
Inmaculada Baeza, Adriana Fortea, Daniel Ilzarbe, et al.
Pediatric Drugs (2023) Vol. 25, Iss. 2, pp. 135-149
Open Access | Times Cited: 10
Clinician differences in attitudes and perceptions on the use of long-acting injectable antipsychotic agents in treating patients with schizophrenia: results from the US DECIDE survey
Dawn I. Velligan, Gregory D. Salinas, Emily Belcher, et al.
BMC Psychiatry (2025) Vol. 25, Iss. 1
Open Access
An analysis of the clinical application of paliperidone palmitate injection based on real-world
Ruixue Liu, Chunxiao Liu, Di Hu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Preparation, characterisation, and testing of reservoir-based implantable devices loaded with tizanidine and lidocaine
Camila J. Picco, Mihir S Bhalerao, Octavio E. Fandiño, et al.
Drug Delivery and Translational Research (2025)
Open Access
Prescribing pattern of antipsychotic medication for first-episode psychosis: a retrospective cohort study
Dolores Keating, Stephen McWilliams, Fiona Boland, et al.
BMJ Open (2021) Vol. 11, Iss. 1, pp. e040387-e040387
Open Access | Times Cited: 21
Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians
Leslie Citrome, Emily Belcher, Sylvie Stacy, et al.
Neuropsychiatric Disease and Treatment (2022) Vol. Volume 18, pp. 111-123
Open Access | Times Cited: 16
Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland
Stephan Reymann, Georgios Schoretsanitis, Stephan Egger, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 3, pp. 441-441
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top